EORTC CLTF 2018 | Targeting PLCG1: a calcineurin inhibitor for early mycosis fungoides

Pablo Ortiz

Mutations in PLCG1 have been associated with mycosis fungoides, making them a good therapeutic target. Here, Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, discusses the use of calcineurin inhibitors to target the affected pathway, which have produced promising results in a Phase II trial. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Ortiz suggests the use of calcineurin inhibitors to treat lymphomas in the future.

Share this video